Alkem Laboratories Ltd - 539523 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Alkem Laboratories Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here Alkem Laboratories Ltd - 539523 - Shareholder Meeting / Postal Ballot-Outcome of AGM
This is with reference to the 45th Annual General Meeting of the Company held on Tuesday, 27th August, 2019 at 10.30 a.m. at Nehru Centre Auditorium, Dr Annie Besant Road, Worli, Mumbai 400 018. Please find enclosed herewith the details regarding the brief proceedings of the 45th Annual General Meeting (AGM) of the Company and the details regarding the voting results of the business transacted at the said AGM in the prescribed format. Further, we are also enclosing the Report of the Scrutinizer on remote e-voting and tablet based e-voting at the AGM. You are requested to take a note of the same. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
This is to inform you that US FDA had conducted inspections at the Company's manufacturing facilities located at St. Louis, Fenton Park, USA from 16th August 2019 to 22nd August, 2019 and Baddi, India from 19th August, 2019 to 23rd August, 2019. At the end of the inspection, the Company has received a Form 483 with four (4) observations for the facility located at St. Louis, Fenton Park, USA and no Form 483 is received for the facility located at Baddi, India. The Company shall put together a detailed response with adequate corrective and preventive measures to address the US FDA Observations for the facility located at St. Louis , Fenton Park, USA and the same is proposed to be filed within the timeline stipulated by US FDA. Kindly take note of the same. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the Securities & Exchange Board of India (Listing Obligation & Disclosure Requirements) Regulations, 2015, we enclose a copy of the newspaper clipping of Notice which appeared on 23rd August, 2019, in the Business Standard- English daily and Mumbai Lakshadeep - Marathi daily in respect of the corrigendum to notice of the 45th Annual General Meeting of the Company. Kindly take the same on record. Alkem Laboratories: The right remedy
Focus on high-margin chronic products and key launches should drive growth Alkem Laboratories: The right remedy
Focus on high-margin chronic products and key launches should drive growth Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Investor Presentation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith press release and analyst presentation on Q1FY20 earnings and business updates and the same will be uploaded on the website of the Company. Kindly take note of the same. Alkem Laboratories Ltd - 539523 - Closure of Trading Window
We refer to our earlier communication dated 28th June, 2019 regarding closure of trading window (for the purpose of financial results for the quarter ended 30th June, 2019) starting from 29th June, 2019 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter ended 30th June, 2019 are communicated to the Stock Exchanges. The Financial Results of the Company for the quarter ended 30th June, 2019 having been communicated to the Stock Exchanges, today i.e. 12th August, 2019, the trading window shall open on 15th August, 2019. Alkem Laboratories Ltd - 539523 - Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended 30Th June, 2019.
In continuation of our letter dated 1st August, 2019 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we are enclosing the Standalone and Consolidated Unaudited Financial Results for the quarter ended 30th June, 2019, duly approved by the Board of Directors of the Company, at its meeting held today, i.e. 12th August, 2019. The meeting of the Board of Directors of the Company commenced at 12.00 noon and concluded at 2.00 P.M. A copy of the Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the Listing Regulations, is also enclosed herewith. Kindly take the same on record. Alkem Laboratories Ltd - 539523 - Outcome of Board Meeting
In continuation of our letter dated 1st August, 2019 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we are enclosing the Standalone and Consolidated Unaudited Financial Results for the quarter ended 30th June, 2019, duly approved by the Board of Directors of the Company, at its meeting held today, i.e. 12th August, 2019. The meeting of the Board of Directors of the Company commenced at 12.00 noon and concluded at 2.00 P.M. A copy of the Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the Listing Regulations, is also enclosed herewith. Kindly take the same on record.